Register for email alerts and news feeds:
This journal | BMJ Group
rss
Journal of Clinical Pathology 2005;58:1086-1090; doi:10.1136/jcp.2004.021576
Copyright © 2005 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

ORIGINAL ARTICLE

IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTestTM in breast carcinoma

R Ainsworth1, J M S Bartlett2, J J Going1, E A Mallon3, A Forsyth2, J Richmond1, W Angerson2, A Watters2 and B Dunne1

1 Department of Pathology, Glasgow Royal Infirmary, Glasgow G4 0SF, UK
2 Endocrine Cancer Group, University of Glasgow G31 2ER, Glasgow, UK
3 Department of Pathology, Western Infirmary, Glasgow G11 6NT, UK

Correspondence to:
Correspondence to:
Dr B Dunne
Department of Pathology, Central Pathology Laboratory, St James’s Hospital, Dublin 8, Ireland; barbaradunne{at}hotmail.com

Background: Her2 (c-erbB-2/neu) overexpression in breast carcinoma predicts response to the anti-Her2 monoclonal antibody, trastuzumab, and is associated with a poor prognosis. When considering patients for trastuzumab treatment, Her2 protein expression is measured by imunohistochemistry (IHC) and, where staining is equivocal, by fluorescence in situ hybridisation (FISH) detection of Her2 gene amplification.

Aims: To compare IHC using CBE356 with IHC using the Food and Drug Administration approved HercepTestTM.

Methods: CBE356 and HercepTest were analysed using 167 FISH characterised breast carcinomas. Immunohistochemical expression of Her2 was measured semiquantitatively. Sensitivity, specificity, predictive values, and overall accuracy were calculated for both IHC methods using gene amplification by FISH as the end point, and IHC and FISH assays were tested in Kaplan–Meier survival analysis.

Results: The accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of CBE356 positive (2+ and 3+) cases were 94%, 89%, 95%, 84%, and 97%, respectively, and of HercepTest positive (2+ and 3+) cases were 91%, 66%, 98%, 92%, and 91%, respectively. A positive result with CBE356, HercepTest, or FISH was associated with significantly decreased overall survival (log rank p = 0.005, p = 0.0017, and p = 0.0005, respectively).

Conclusions: Positive IHC staining for Her2 using CBE356 is 3% more accurate and 23% more sensitive at predicting Her2 gene amplification by FISH than positive staining with HercepTest. Negative IHC using CBE356 antibody is 6% more likely to represent a truly negative result than negative staining with HercepTest. Overall, CBE356 was a more accurate predictor of Her2 gene amplification by FISH than HercepTest.

Abbreviations: CI, confidence interval; FDA, Food and Drug Administration; FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry

Keywords: CBE356; immunohistochemistry; Her expression; breast carcinoma


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Egervari, K, Szollosi, Z, Nemes, Z (2006). Reply to "IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTestTM in breast carcinoma". J. Clin. Pathol. 59: 665-665 [Full Text]  
  • Dunne, B (2006). Reply to Egervari et al "IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTestTM in breast carcinoma". J. Clin. Pathol. 59: 665-666 [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Pathology jobs

Pathology jobs